SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present preclinical data on its ACP-104 schizophrenia program, its ACP-105 Selective Androgen Receptor Modulator (SARM) program, and its muscarinic discovery program at the Experimental Biology 2008 Meeting to be held from April 5-9, 2008 in San Diego, California, and the related Satellite Symposium on Recent Advances in Muscarinic Receptor Pharmacology and Therapeutics to be held from April 4-5, 2008.
